<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>21(6)</volume><submitter>Jalian HR</submitter><funding>Allergan</funding><pubmed_abstract>&lt;h4>Background&lt;/h4>Submental fat (SMF) detracts from facial aesthetics and negatively impacts self-image.&lt;h4>Aims&lt;/h4>To evaluate safety, effectiveness, and satisfaction of cryolipolysis and ATX-101 used sequentially to reduce SMF.&lt;h4>Methods&lt;/h4>A prospective, open-label, interventional, single-site study enrolling 22- to 65-year-old participants rated as Grade 4 (extreme) on the Clinician-Rated SMF Rating Scale (CR-SMFRS). Co-primary effectiveness endpoints were proportions of participants with ≥1-grade and ≥2-grade improvement on CR-SMFRS at 12 weeks post final treatment. Additional assessments included ultrasound measurement of fat thickness and Subject Self-Rating Scale (SSRS) scores at 12 weeks post final treatment. Safety was assessed throughout the study.&lt;h4>Results&lt;/h4>Of 16 enrol</pubmed_abstract><journal>Journal of cosmetic dermatology</journal><pagination>2437-2444</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9325515</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Submental fat reduction using sequential treatment approach with cryolipolysis and ATX-101.</pubmed_title><pmcid>PMC9325515</pmcid><pubmed_authors>Bowen B</pubmed_authors><pubmed_authors>Fitzgerald R</pubmed_authors><pubmed_authors>Jalian HR</pubmed_authors><pubmed_authors>Gamio S</pubmed_authors></additional><is_claimable>false</is_claimable><name>Submental fat reduction using sequential treatment approach with cryolipolysis and ATX-101.</name><description>&lt;h4>Background&lt;/h4>Submental fat (SMF) detracts from facial aesthetics and negatively impacts self-image.&lt;h4>Aims&lt;/h4>To evaluate safety, effectiveness, and satisfaction of cryolipolysis and ATX-101 used sequentially to reduce SMF.&lt;h4>Methods&lt;/h4>A prospective, open-label, interventional, single-site study enrolling 22- to 65-year-old participants rated as Grade 4 (extreme) on the Clinician-Rated SMF Rating Scale (CR-SMFRS). Co-primary effectiveness endpoints were proportions of participants with ≥1-grade and ≥2-grade improvement on CR-SMFRS at 12 weeks post final treatment. Additional assessments included ultrasound measurement of fat thickness and Subject Self-Rating Scale (SSRS) scores at 12 weeks post final treatment. Safety was assessed throughout the study.&lt;h4>Results&lt;/h4>Of 16 enrol</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Jun</publication><modification>2025-04-18T15:36:52.205Z</modification><creation>2025-04-07T02:20:29.318Z</creation></dates><accession>S-EPMC9325515</accession><cross_references><pubmed>35278262</pubmed><doi>10.1111/jocd.14909</doi></cross_references></HashMap>